SCHEMBL22869810

SCHEMBL22869810

CC(C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]1O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
CD209 Q9NNX6 1/20 0.45
LGALS8 O00214 1/20 0.44
LGALS3 P17931 1/20 0.44
LGALS4 P56470 1/20 0.44
GJA1 P17302 1/20 0.43
GJB2 P29033 1/20 0.43
CYP2C9 P11712 1/20 0.43
TSHR P16473 1/20 0.43
ALDH1A1 P00352 1/20 0.43
ENGASE Q8NFI3 1/20 0.43
FGF1 P05230 1/20 0.42
FGF2 P09038 1/20 0.42
VEGFA P15692 1/20 0.42
HPSE Q9Y251 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TYR P14679 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22869440 1.00 MEN1 (0.48) MEN1KMT2ACD209LGALS8LGALS3
SCHEMBL24211442 1.00 MEN1 (0.48) MEN1KMT2ACD209LGALS8LGALS3
SCHEMBL22869811 1.00 MEN1 (0.48) MEN1KMT2ACD209LGALS8LGALS3
SCHEMBL22869540 0.97 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL22869547 0.97 MEN1 (0.50) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL24211412 0.93 MEN1 (0.43) MEN1KMT2ACD209LGALS8LGALS3
SCHEMBL24211582 0.93 MEN1 (0.47) MEN1KMT2ACD209LGALS8LGALS3
SCHEMBL22869798 0.93 LGALS8 (0.52) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL22869799 0.93 LGALS8 (0.52) MEN1KMT2ALGALS8LGALS3LGALS4
SCHEMBL22869772 0.93 MEN1 (0.47) MEN1KMT2ACD209LGALS8LGALS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017557-A1 HIGH-PURITY STEVIOL GLYCOSIDES PURECIRCLE USA INC. 2022-01-20 US disclosed
US-20210002318-A1 HIGH-PURITY STEVIOL GLYCOSIDES PURECIRCLE USA INC. (US) 2021-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210002318-A1 HIGH-PURITY STEVIOL GLYCOSIDES TAS2R7, ADH1C, TAS2R42 MEN1 3378/4885KMT2A 1150/4885CD209 3084/4885
US-20220017557-A1 HIGH-PURITY STEVIOL GLYCOSIDES TAS2R7, ADH1C, SUCLG2 MEN1 3263/4885KMT2A 1819/4885CD209 1869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.